Francesco Pieri

Francesco Pieri

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2005 in Journal of Micromechanics and Microengineering
Verified
Journal Article
Closed access
Giuseppe BarillaroGiuseppe Barillaro
Giuseppe Barillaro
AMAntonio Molfese
Antonio Molfese
ANAndrea Nannini
Andrea Nannini
FPFrancesco Pieri
Francesco Pieri

8 April 2003 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
Giuseppe BarillaroGiuseppe Barillaro
Giuseppe Barillaro
ANA. Nannini
A. Nannini
FPFrancesco Pieri
Francesco Pieri

1 April 2014 in Journal of Micromechanics and Microengineering
Verified
Journal Article
Closed access
LLLuca Luschi
Luca Luschi
FPFrancesco Pieri
Francesco Pieri

1 January 2002 in Journal of the Electrochemical Society
Verified
Journal Article
Closed access
PDF file
Giuseppe BarillaroGiuseppe Barillaro
Giuseppe Barillaro
ANA. Nannini
A. Nannini
FPFrancesco Pieri
Francesco Pieri
The fabrication of macropores in crystalline silicon by photoelectrochemical etching in a hydrofluoric acid electrolyte is investigated. It is shown that the dimensional constraints on the pore diameters, which, in previous literature, are considered to depend on substrate doping, can be significantly relaxed. We show that it is possible to fabricate arrays of square section macropores with sides ranging from 2 to 15 μm using the same n-doped (2.4-4 Ω cm) silicon substrate. Moreover, we demonstrate that macropore arrays with pitch variation up to 100% (8 and 16 μm) can be simultaneously grown on the same silicon sample. The same process is used to fabricate arrays of silicon walls with different spacing and pitch as well. A simple model, based on the coalescence in a single pore of multiple stable pores, is proposed to explain the experimental data. © 2002 The Electrochemical Society. All rights reserved.

27 April 2007 in Physica Status Solidi (a)
Verified
Journal Article
Closed access
PDF file
Giuseppe BarillaroGiuseppe Barillaro
Giuseppe Barillaro
PBPaolo Bruschi
Paolo Bruschi
FPFrancesco Pieri
Francesco Pieri
LSL. M. Strambini
L. M. Strambini

5 September 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
MMMariangela Morelli
Mariangela Morelli
Francesca LessiFrancesca Lessi
Francesca Lessi
SBSerena Barachini
Serena Barachini
RLRomano Liotti
Romano Liotti
Nicola MontemurroNicola Montemurro
Nicola Montemurro
Chiara Maria MazzantiChiara Maria Mazzanti
Chiara Maria Mazzanti
Background: Glioblastoma (GB) is the most severe form of brain cancer, with a 12-15 month median survival. Surgical resection, temozolomide (TMZ) treatment, and radiotherapy remain the primary therapeutic options for GB, and no new therapies have been introduced in recent years. This therapeutic standstill is primarily due to preclinical approaches that do not fully respect the complexity of GB cell biology and fail to test efficiently anti-cancer treatments. Therefore, better treatment screening approaches are needed. In this study, we have developed a novel functional precision medicine approach to test the response to anticancer treatments in organoids derived from the resected tumors of glioblastoma patients.Methods: GB organoids were grown for a short period of time to prevent any genetic and morphological evolution and divergence from the tumor of origin. We chose metabolic imaging by NAD(P)H fluorescence lifetime imaging microscopy (FLIM) to predict early and non-invasively ex-vivo anti-cancer treatment responses of GB organoids. TMZ was used as the benchmark drug to validate the approach. Whole-transcriptome and whole-exome analyses were performed to characterize tumor cases stratification.Results: Our functional precision medicine approach was completed within one week after surgery and two groups of TMZ Responder and Non-Responder tumors were identified. FLIM-based metabolic tumor stratification was well reflected at the molecular level, confirming the validity of our approach, highlighting also new target genes associated with TMZ treatment and identifying a new 17-gene molecular signature associated with survival. The number of MGMT gene promoter methylated tumors was higher in the responsive group, as expected, however, some non-methylated tumor cases turned out to be nevertheless responsive to TMZ, suggesting that our procedure could be synergistic with the classical MGMT methylation biomarker.Conclusions: For the first time, FLIM-based metabolic imaging was used on live glioblastoma organoids. Unlike other approaches, ex-vivo patient-tailored drug response is performed at an early stage of tumor culturing with no animal involvement and with minimal tampering with the original tumor cytoarchitecture. This functional precision medicine approach can be exploited in a range of clinical and laboratory settings to improve the clinical management of GB patients and implemented on other cancers as well.